Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Carpenter

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The Surgical Clinics of North America|November 21, 2022
New Technology for the Breast SurgeonMichele Carpenter, Julie Le
Clinical Breast Cancer|December 17, 2008
BRCA mutations and the risk of angiosarcoma after breast cancer treatmentJohn G West, Jeffrey N Weitzel, May Lin Tao, et al.
Brachytherapy|October 17, 2017
A prospective phase I comparison of toxicity and cosmesis outcomes of single-fraction IORT and hypofractionated radiotherapy with IORT boost in early-stage breast cancerTanuja Bhandari, Wesley Babaran, Afshin Forouzannia, et al.
Brachytherapy|June 26, 2019
Recurrence rates for patients with early-stage breast cancer treated with IOERT at a community hospital per the ASTRO consensus statement for APBIVenita L Williams, Tanuja Bhandari, Lillian J Chen, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The Surgical Clinics of North America|November 21, 2022
New Technology for the Breast SurgeonMichele Carpenter, Julie Le
Clinical Breast Cancer|December 17, 2008
BRCA mutations and the risk of angiosarcoma after breast cancer treatmentJohn G West, Jeffrey N Weitzel, May Lin Tao, et al.
Brachytherapy|October 17, 2017
A prospective phase I comparison of toxicity and cosmesis outcomes of single-fraction IORT and hypofractionated radiotherapy with IORT boost in early-stage breast cancerTanuja Bhandari, Wesley Babaran, Afshin Forouzannia, et al.
Brachytherapy|June 26, 2019
Recurrence rates for patients with early-stage breast cancer treated with IOERT at a community hospital per the ASTRO consensus statement for APBIVenita L Williams, Tanuja Bhandari, Lillian J Chen, et al.
Pageof 1